Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Antihemophilic Factor, Human Recombinant 1 UNT Injection [Advate]

Known as: Advate 1 UNT Injection, ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 50 [iU] in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ADVATE], ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 800 [iU] in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ADVATE] 
 
National Institutes of Health

Related topics

Related topics

13 relations
AdvateAntihemophilic Factor, Human RecombinantCalcium ChlorideFactor VIII
Expand

Broader (1)

Antihemophilic Factor, Human Recombinant 1 UNT Injection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Estimation of Nuwiq® (simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study
Accurate determination of coagulation factor VIII activity (FVIII:C) is essential for effective and safe FVIII replacement… Expand
2018
2018
Perioperative safety and hemostatic efficacy of Advate® in patients with hemophilia A in a postmarketing surveillance in Japan
Rurioctocog alfa (recombinant factor VIII: Advate®) is available for the control of bleeding among patients with hemophilia A in… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2012
2012
Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A
Summary We report a prospective trial of 55 previously untreated patients (PUPs) and minimally treated patients (MTPs) with… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2012
2012
Octocog Alfa (Advate®): A Guide to Its Use in Hemophilia A
Prophylaxis or on-demand therapy with octocog alfa, antihemophilic factor, plasma/albumin-free method (Advate®) is effective for… Expand
  • table I
  • table II
  • table III
  • table IV
2011
2011
Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys
Abstract 4346 The pharmacokinetic profile of BAX 855, a longer acting PEGylated variant of Baxter’s recombinant FVIII based on… Expand
2011
2011
Society on Thrombosis and Haemostasis Kioto ( Japonia ) , 23 – 28 lipca 2011 roku
  • M. Łętowska, wybranych zagadnień, Nowe rekombinowane białka
  • 2011
    • Corpus ID: 62860136
Nowe rekombinowane białka Rekombinowany czynnik VIII Powell i wsp. przedstawili wyniki otwartego, wieloośrodkowego badania z… Expand
2010
2010
Functional characteristics of N8, a new recombinant FVIII
Summary.  The aim of this study was to evaluate the in vitro function of the new recombinant factor VIII (FVIII) compound, N8… Expand
2009
2009
Xyntha® is effective and safe in previously treated patients with severe haemophilia A: Final results of a pivotal phase III study
Background:  Xyntha® (albumin-free cell culture process) is a BDDrFVIII manufactured using an albumin-free cell culture process… Expand
2005
2005
Economic and Epidemiological Modelling of Full-Length Antihaemophilic Factor (Recombinant), Plasma/Albumin-Free Method, in Previously Treated Patients with Haemophilia A
AbstractObjectives: To the extent that current recombinant clotting factor concentrates contain even trace amounts of human or… Expand
2004
2004
Twelve Month Post Licensure Safety and Efficacy Data of Advate rFVIII PFM.
Initial data on safety and efficacy of new therapeutic agents are provided by formal clinical research studies. These provide… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE